Skip to content
ppharmaranks
Menu

Necitumumab: uses, dosing, side effects & brands

Necitumumab is a medicine sold in the U.S. under one brand. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.

By the pharmaranks editorial teamReviewed against the FDA (openFDA label, NDC Directory & Enforcement) sourcesUpdated Jul 24, 2026How we research

Key facts

Available as
Injectable
Sold as
Portrazza
Prescription?
Prescription only
Generic available?
Not in our catalog

Every necitumumab product we track (1)

Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.

Only one: Portrazza.

Necitumumab and breastfeeding

From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.

No information is available on the clinical use of necitumumab during breastfeeding. Because necitumumab is a large protein molecule with a molecular weight of 145,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant. However, the manufacturer recommends that women receiving necitumumab should not breastfeed during therapy or for 3 months following the final dose.

Full LactMed record for necitumumab: levels in milk, effects in breastfed infants, and the drugs it would consider instead

National Institute of Child Health and Human Development, record revised November 15, 2023. LactMed states its information is not a substitute for professional judgement.

What people report to the FDA about necitumumab

The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 513 reports naming necitumumab, and the FDA flagged 99% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:

  • platelet count decreased72 reports
  • hypomagnesaemia60 reports
  • malignant neoplasm progression58 reports
  • neutrophil count decreased51 reports
  • rash47 reports
  • dermatitis acneiform44 reports
  • neutropenia41 reports
  • febrile neutropenia39 reports

Read these as a signal, not a rate. A report does not mean necitumumab caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.

Source: openFDA drug/event (FAERS), retrieved July 25, 2026.

Related calculators

Frequently asked questions

Can you take necitumumab with other medicines?

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run necitumumab against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

What forms does necitumumab come in?

Across the brands we track, necitumumab is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Is there a generic necitumumab?

We do not currently list a generic-labelled necitumumab product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.

Cite this page
APA
pharmaranks. (2026, July 24). Necitumumab: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/necitumumab
MLA
“Necitumumab: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/necitumumab.

We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.

Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.

Read the full FDA label for necitumumab on DailyMed (NIH) ↗.